Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS Trial.

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS Trial.

<h4>Objective</h4> <p>Type 2 diabetes is associated with increased fracture risk, further elevated by treatments such as thiazolidinediones and sodium-glucose co-transporter-2 inhibitors. As data regarding dipeptidyl peptidase-4 inhibitors are mixed, we examined fracture incidence...

Full description

Bibliographic Details
Main Authors: Josse, R, Majumdar, S, Zheng, Y, Adler, A, Bethel, M, Buse, J, Green, J, Kaufman, K, Rodbard, H, Tankova, T, Westerhout, C, Peterson, E, Holman, R, Armstrong, P
Format: Journal article
Language:English
Published: Wiley 2016

Similar Items